Podcasts about ons

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

Join Office of Neighborhood Safety in this episode as we celebrate Safe Summer Nights at St. Paul's El Rio Community Center! Today we are highlighting community, partnerships, and feedback. Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Send us a textJakobus 3:13 Is daar 'n wyse en verstandige mens onder julle? Dan moet hy dit toon deur sy goeie gedrag en deur dade wat van nederigheid en wysheid getuig. Ons het almal al mense ontmoet wat ons sonder twyfel as wys sou beskryf. Maar ons praat nie nou van selfsugtige, arrogante persone as wys nie. So wat beteken dit dan eintlik om wys te wees?Sommige mense lyk ongelooflik bekwaam. Hulle het die gawe om komplekse probleme op te los en suksesvolle uitkomste te bewerk. En hulle is dikwels kragtige kommunikeerders; hulle is in staat om ander mense te beïnvloed. Is dít wat dit beteken om wys te wees? Wel, miskien ... maar net gedeeltelik. Adolf Hitler was op die kruin van sy sukses so 'n persoon, totdat dit alles tot niet gegaan het. Nee, wysheid behels beslis nie hierdie wêreldse wysheid nie. Jakobus 3:13 Is daar 'n wyse en verstandige mens onder julle? Dan moet hy dit toon deur sy goeie gedrag en deur dade wat van nederigheid en wysheid getuig.So, ware wysheid, vanuit God se perspektief, behels wel begrip. Maar dis 'n begrip wat ons lei om reg te lewe; sodat ons deur ons goeie gedrag; deur ander te dien; deur die dinge wat ons in nederigheid doen, uiteindelik ons wysheid sal uitleef. Dink aan die leiers in jou wêreld, in jou werkplek, in jou gemeenskap. Word hulle gekenmerk deur nederigheid en goedheid, of is dit hulle grootpratery en gespog wat vir hulle korttermyn sukses bring? Ja-nee, moenie 'n fout maak nie, as dit laasgenoemde is, sal hulle sukses inderdaad van korte duur wees. En hier is die vraag vir jou: is jy werklik wys en ondersteunend? Indien wel ... moet jy met nederigheid wys optree. Onthou, 'n wyse persoon spog nie. Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Send us a textMatteus 4:18-20 Eendag toe Jesus langs die See van Galilea loop, sien Hy twee broers: Simon, wat ook Petrus genoem word, en sy broer Andreas. Hulle was besig om 'n werpnet in die see uit te gooi, want hulle was vissers van beroep. Hy sê toe vir hulle: “Kom hier! Kom saam met My, en Ek sal julle vissers van mense maak.” Hulle het dadelik die nette gelos en Hom gevolg. Het jy al ooit ‘n doelwit probeer bereik – iets wat jy regtig graag wou bereik – maar toe dinge moeilik raak, toe jy teenstand ervaar het; toe jy moeg geword het vir die gesukkel … het jy moed verloor? Wel, jy is nie die enigste een nie.In 1405 het die Chinese keiser, Yongle van die Ming-dinastie, vir ‘n sekere Admiraal Zheng opdrag gegee om 'n reeks ontdekkingsreise te lei om die Chinese handel uit te brei. Maar na keiser Yongle se dood het die nuwe leier skepties en halfhartig oor skeepvaart gevoel en die befondsing en hulpbronne vir reise verminder. En as 'n direkte gevolg van sy louwarm houding, het China die geleentheid om wêreldwye maritieme handel vir eeue te oorheers, misgeloop.Dit het al talle kere op 'n geopolitieke skaal gebeur. Ons kan self stories vertel van wat met mense wat ons ken, wat tou opgegooi het, gebeur het. Daardie gebrek aan toewyding lei elke keer tot mislukking.Matteus 4:18-20 Eendag toe Jesus langs die See van Galilea loop, sien Hy twee broers: Simon, wat ook Petrus genoem word, en sy broer Andreas. Hulle was besig om 'n werpnet in die see uit te gooi, want hulle was vissers van beroep. Hy sê toe vir hulle: “Kom hier! Kom saam met My, en Ek sal julle vissers van mense maak.” Hulle het dadelik die nette gelos en Hom gevolg.Hulle het alles laat vaar, hulle rug gedraai op die besigheid wat hulle vader opgebou het en wat hulle eendag sou erf. Ja, hulle het vir Jesus gevolg op 'n onsekere, ongemaklike pad, wat op die ou end hul lewens gekos het. Dit het alles begin met die roepstem van Jesus. Hulle het geantwoord. Hulle het tot die einde volhard.‘n Mens kan nie ligtelik besluit om Hom te volg nie; Jesus roep jou nie tot 'n gemaklike, afgewaterde geloof nie, maar tot 'n lewenslange verbintenis deur dik en dun.Simon en Andreas het dadelik hulle nette gelos en Hom gevolg.Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Slotbetoë word aangehoor in Tiffany Meek se borgaansoek. 'n Wysigingswetsontwerp wat die afskaffing van adjunkministersposte voorstel, is in die Staatskoerant gepubliseer. Ons bekyk die handelsooreenkoms tussen Amerika en die Europese Unie. 'n Studie deur Wits wys dat klimaatsverandering die verwoestende storms in 2022 vererger het.

Ons hoef nie te presteer nie. Ons hoef Hom nie te beïndruk nie. Ons kan net by Hom tuiskom.

Send us a textJesaja 48:17 So sê die Here, jou Verlosser, die Heilige van Israel: Ek is die Here jou God wat jou onderrig tot jou beswil, wat jou lei op die pad waarop jy moet gaan. Nie een van ons hou daarvan om voorgesê te word wat om te doen nie. Ons het nie daarvan gehou toe ons kinders was nie, en ons hou beslis nie daarvan noudat ons almal groot is nie.Ek het onlangs iets op sosiale media gesien wat soos volg gelui het: Moenie dat iemand wat nie in jou skoene geloop het vir jou vertel hoe om jou veters vas te maak nie. Kyk, ek verstaan die begrip, maar ‘n mens kan dit, tot jou eie nadeel, heeltemal te ver voer.Ons trots - die gevoel van selfgeregtigheid waar ons ons tekortkominge goedpraat, kan uiteindelik ons harte afstomp en onleerbaar maak - doof vir die goeie raad van ander en inderdaad vir die raad van God self.Luister dus asseblief vir 'n oomblik terwyl God uitreik om ons harte sag te maak en ons verstand oop te maak.Jesaja 48:17 So sê die Here, jou Verlosser, die Heilige van Israel: Ek is die Here jou God wat jou onderrig tot jou beswil, wat jou lei op die pad waarop jy moet gaan.Dink jy God sê vir ons dinge om ons lewens te benadeel, of om ons te seën? Gee Hy, soos enige goeie pa, vir ons opdragte om met ons koppe te smokkel, of om ons vir ons eie beswil te leer?Een van die ergste situasies waarin ons onsself kan bevind, is daardie hardnekkige situasie; daardie situasie waar ons ons harte verhard vir sy liefde, 'n liefde wat verder strek as enigiets wat ons ooit sal kan begryp. So, asseblief: luister... asseblief...Ek is die Here jou God wat jou onderrig tot jou beswil, wat jou lei op die pad waarop jy moet gaan.Dis Sy Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Op het moment dat jullie dit luisteren bewaakt Gijsje het fort (de Saarredactie), zit Barbara met haar man, twee zonen en aanhang van de oudste in Thailand en probeert Femke met haar gezin het (hopelijk niet zo bloedhete) Frankrijk weer eens uit. We reten schoenen. Volgens Barbara best wel een ding, want vroeger dartelde ze vrolijk rond op hoge hakken, maar door haar moeilijke voeten is een goeie schoen vinden een crime geworden. Femke heeft vrij weinig met schoenen en draagt eigenlijk altijd dezelfde gympen. Ons fragment is geschreven door onze overleden vriendin en collega Els Rozenbroek. Het gaat over euthanasie en de meningen lopen hierover uiteen. Femke vraagt zich af of je Alzheimer niet zijn natuurlijke beloop kunt laten gaan, maar Barbara ziet van dichtbij hoe ontzettend schrijnend dat is. Onze gast is seksualiteitscoach Andrea Davelaar, die ons komt leren hoe je weer zin in een lekker potje vrijen krijgt. Andrea biedt 1:1 coachingstrajecten aan (met de titel 'Stralend in je eigen seksualiteit') Neem snel een kijkje op haar Instagram @ohmygoddesscoach.Adverteren?Wil je adverteren in deze podcast? Stuur dan een mailtje naar adverteren@bienmedia.nl.

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Welkom bij een nieuwe aflevering van onze podcast met als missie: de online automotive beter maken. Stefanie van Dijk spreekt met vrouwen die werkzaam zijn in de autobranche. Een aflevering door vrouwen, over vrouwen, in een wereld die vaak nog als mannelijk wordt gezien. Te gast is Dianne van der Veen, Business Development Manager bij PowerKraut. “Tijdens mijn studie werkte ik bij een bedrijf dat chats beantwoordde voor autobedrijven. Daar liep ik stage en daarna ben ik gebleven. Zo rolde ik de autobranche in. Na mijn verhuizing naar Arnhem zocht ik werk dichter bij huis. Dat werd PowerKraut. Inmiddels werk ik er zeven jaar, begonnen als projectmanager.”  Van uitvoerend naar strategisch "PowerKraut richt zich op de mobiliteitsbranche. Zo'n 90% van onze klanten zit in de autobranche, van dealers tot importeurs. De afgelopen jaren hebben we ons verbreed richting bijvoorbeeld fietsen en laadoplossingen. Onze rol is mee veranderd. Waar we vroeger vooral uitvoerend werk deden – snel iets regelen en uitvoeren – zijn we nu veel strategischer actief. We worden ingezet om mee te denken en adviseren, en klanten maken gebruik van onze kennis om betere keuzes te maken."  Brede expertise in vier pijlers "Ons bureau bestaat uit vier pijlers: websites & applicaties, marketing automation & data, performance marketing en retailcommunicatie. We stellen per klant een multidisciplinair team samen en volgen de laatste trends in elk vakgebied. Inmiddels werken we met tachtig collega's. We borgen kennis via een interne kennisbank en kennissessies."  De impact van AI en veranderende samenwerking  "AI is een dominante factor geworden, voor ons én onze klanten. Grote bedrijven doen steeds meer in eigen huis, en dat is logisch. Wij maken nu vaker de blauwdruk, terwijl het interne team van de klant de uitvoering op zich neemt. Dat vraagt om een andere vorm van samenwerking, gebaseerd op vertrouwen." Samen groeien "Ik werk graag met klanten die zelf ook kennis in huis hebben. Dan kun je echt de diepte in. Maar ook als dat niet zo is, leveren we kwaliteit – met inzicht in cijfers, zodat er gestuurd kan worden. Uiteindelijk wil elk bedrijf weten: hoeveel leads zijn er, en wat heeft het opgeleverd?"  Van losse data naar 360-graden klantbeeld "Bij klanten brengen we databronnen samen in de cloud. Vaak zit waardevolle klantdata verspreid over systemen die niet met elkaar praten. Wij helpen met ontdubbelen, logica toevoegen en het creëren van één helder klantbeeld. Dat vraagt ook om herinrichting van systemen, want slechte invoer betekent slechte output. Zulke projecten zijn nooit helemaal ‘af', maar moeten wel goed aansluiten op bedrijfsdoelen."  Veranderende markt, nieuwe ambitie  "De bureaumarkt verandert snel. Dankzij tools kunnen bedrijven meer zelf. Je moet als bureau blijven meebewegen. Wij zijn bezig met een aangescherpte propositie en willen ook internationaal uitbreiden. We groeien graag mee met onze klanten." Relaties bouwen op vertrouwen  "Een goede samenwerking betekent ook dat je iets durft af te raden, zelfs als dat commercieel niet handig is. Vertrouwen bouw je op door eerlijk te zijn en het belang van de klant voorop te zetten – ook als dat betekent dat een project later of anders wordt gestart." Leiderschap en ontwikkeling  "Micromanagement past niet bij mij. Ik wil inspireren, meedenken en als sparringpartner optreden. Binnen PowerKraut is die ruimte er, anders had ik hier niet zo lang gewerkt. Ik ontwikkel me nu meer als manager, geef leiding aan het marketing- en contentteam, en dat vraagt een andere manier van werken dan in een uitvoerende rol." Trots op wie we zijn gebleven  "Ik ben trots op hoe we zijn gegroeid, zonder onze cultuur te verliezen. We zijn nog steeds het nuchtere, ondernemende bureau dat we altijd waren. We zetten ons bewust af tegen de ‘hippe' bureaus met veel Engelse termen. Bij ons is het gewoon, menselijk en normaal." Tot slot, voor wie nieuw is in de branche  "Laat je niet tegenhouden omdat je weinig van auto's weet. De autobranche is marketingtechnisch juist interessant: het gaat om bewuste, dure keuzes. Je hoeft geen technische kennis te hebben om goed advies te geven. Het draait eerder om de vraag: leasen, kopen of financieren?" "En: zet altijd een stap extra. Als dat wordt gewaardeerd, zit je op de juiste plek. Zo niet, kijk dan verder. Initiatief tonen levert altijd nieuwe kansen op."

Die Toedelingswetsontwerp word in die Nasionale Vergadering goedgekeur. Die Wes-Kaapse landbousektor wag in spanning op die 30%-tarief wat op 1 Augustus deur die VSA ingestel word. Ons praat hieroor met die bestuurshoof van Agri Wes-Kaap. Die VSA is 'n tree nader om sanksies teen die ANC-leierskap in te stel.

Send us a text1 Konings 20:11 Die koning van Israel antwoord hom: “Hulle sê: 'n Soldaat wat nog aantrek vir die geveg moenie spog soos een wat alreeds oorwin het nie.”(NLV) Om in 'n argument betrokke te raak, is een van die beste maniere om jouself in die moeilikheid te laat beland. Ek het gesien hoe mense die geleentheid geniet; hoe hulle vol vertroue instorm met die idee dat hulle die stryd gaan wen - net om sleepvoetend daar uit te stap en hulle wonde te moet gaan lek. Het jy al ooit selfvoldaan in ‘n stryery betrokke geraak? Ek het op my dag, al op meer as een geleentheid met te veel selfvertroue daarin betrokke geraak, maar glo my: dit is nie iets wat ek graag sal wil herhaal nie. Moet my nie verkeerd verstaan nie, ek is nie ‘n lafhartige bangbroek nie. Trouens, ek het nogal 'n sterk persoonlikheid. My naam – Bernhard – beteken ‘sterk soos 'n beer'.Maar wanneer ons konflik te vinnig en met te veel selfvertroue benader, en oortuig voel dat óns reg is, vertroebel daardie trots ons oordeel; dit verblind ons vir die gevare wat voorlê. Ons lees in die Ou Testament in:1 Konings 20:11 Die koning van Israel antwoord hom: “Hulle sê: 'n Soldaat wat nog aantrek vir die geveg moenie spog soos een wat alreeds oorwin het nie.” (NLV)Koning Agab se argument is dat dit onverstandig is om met 'n oorwinning te spog, voordat die geveg begin het. Dié een wat vir die geveg voorberei deur sy gevegsuniform aan te trek, moenie spog soos iemand wat reeds gewen het nie.Met ander woorde: dit is baie makliker om 'n argument te begin as om een te wen. Natuurlik is konflik soms onvermydelik. Soms moet jy inderdaad jou man staan. Maar daardie tye is meer die uitsondering as die reël.Jesus het die grootste geveg in die ganse geskiedenis gewen deur te weier om te veg. Hy het mense, soos ek en jy gered, deur Homself oor te gee aan die dood aan 'n Kruis en God toe te laat om die oorwinning te behaal, deur Hom weer op die derde dag op te wek.Moenie gevegte veg tensy jy absoluut móét nie. En moet beslis nie met oorwinning spog terwyl jy nog besig is om jou gevegsuniform aan te trek nie.Dis God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Jesus is die Lig van hierdie wêreld. Jy en ek is Ligdraers. Ons steek kerse van hoop op waar wanhoop seëvier.

Send us a textLukas 2:49, 50 “Maar hoekom was dit nodig om te soek?” het Hy gevra. “Julle moes geweet het Ek sou in my Vader se huis wees.” Maar hulle het nie verstaan wat Hy bedoel nie. (NLV) Mag ek jou vandag vra: Wat is jou doel in die lewe? Wat gee betekenis aan jou bestaan? Is dit net om jouself gelukkig te maak? Want, 'n lewe wat daarop gerig is om slegs jou eie begeertes te bevredig, en om jouself gelukkig te maak, is een van die leegste, mees onbevredigende lewens wat jy jouself ooit kan voorstel.So, laat ek weer vra, Wat is jou doel? Wat doen jy vir ander mense deur jou unieke, Godgegewe gawes en vermoëns te gebruik om hul lewens te seën en te verryk?Op twaalfjarige ouderdom het Jesus in Jerusalem soek geraak. Stel jou Josef en Maria se paniek voor: "Ons het die Verlosser van die wêreld verloor. En wat sal God sê as Hy sien dat ons hierdie een verantwoordelikheid wat Hy vir ons gegee het, nie nagekom het nie? Maar toe hulle Hom uiteindelik kry, ...Lukas 2:49 “Maar hoekom was dit nodig om te soek?” het Hy gevra. “Julle moes geweet het Ek sou in my Vader se huis wees.” Maar hulle het nie verstaan wat Hy bedoel nie. (NLV).Reeds van 'n baie jong ouderdom af het Jesus baie duidelik geweet wat sy doel in die lewe was en Hy het nie vir ‘n oomblik daaroor getwyfel nie. Wat 'n rolmodel!C.S. Lewis het eenkeer gesê: Die wêreld kan binne tien minute tot ‘n einde kom; intussen moet ons voortgaan om ons plig te doen. Die grootste ding is om as 'n kind van God op jou pos te wees; elke dag te leef asof dit jou laaste is, maar om terselfdertyd te beplan asof die wêreld nog 'n honderd jaar lank gaan voortbestaan.Dis ‘n groot versoeking om ons lewens te leef asof óns die middelpunt van die heelal is; en dat ál wat tel: óns gemak, óns behoeftes en óns toekoms is. Maar my vriend, dis beslis nie waarvoor ons op hierdie aarde geplaas is nie. God het jou geskep, jou geseën en jou geroep om iets unieks te doen en tot seën vir ander te wees. Spring in en doen dit!Dit is God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Kijk in deze nieuwe video van Voice Faith naar lesavond 22 van de Holy Spirit School. God heeft jou een Helper gezonden die relatie met jou wil bouwen. Leer Hem kennen, vertrouwen en groei in de vruchten en gaven van de Geest om met kracht Gods Koninkrijk te bouwen en sterk te staan in alles wat God voor je heeft.Heb je gebed nodig? Ons gebedsteam staat voor je klaar! ☎️De gebedslijn is iedere dinsdagavond tussen 19:30 en 21:00 uur geopend: BEL (085) 488 2323Kijk voor meer info over de gebedslijn: https://frontrunnersministries.nl/gebed/Kijk iedere week naar Voice of Faith LIVE om 20:00.

With migration continuing to make headlines in the media, we unpack what actually defines a “migrant”, and how the UK's largest producer of official statistics goes about counting them.  We also shed light on the misuse of migration figures.    Transcript    MILES FLETCHER  Hello and a very warm welcome to a new series of Statistically Speaking - the official podcast of the UK Office for National Statistics. This is where we hear from the people producing the nation's most important numbers, about how they do it and what the statistics are saying.   Now it's hard to think of one statistic that could be said to have been more influential these past few years than net international migration. Suffice to say it's the one ONS statistic that probably draws more media attention than any other.  But to fully understand the migration figures, and the swirling debate around them, we'd say it pays to know a little about how they are put together. And the first thing you need to know about that is what, or who, is a migrant in the first place. As usual, to unpack and explain the migration statistics we have the top experts from the ONS and beyond. Mary Gregory is director of population statistics here at the ONS. Madeleine Sumption is director of the Migration Observatory at the University of Oxford, and new chair of the National Statistician's Advisory Panel on Migration. And to help us understand how the numbers are used and abused in public debate, we're also delighted to welcome Hannah Smith, senior political journalist at fact checking charity Full Fact. Welcome to you all.   Madeleine, to start with you if I may, with that fundamental question, quite simply, what is a migrant?   MADELEINE SUMPTION  Well, there are actually lots of different definitions of a migrant and we use different definitions at different points in time. The standard definition of migration that we use in this country is long term migration, so people moving for at least 12 months, and so the Office for National Statistics figures on immigration, emigration and net migration are all using that definition. And people in that data, they're migrants regardless of whether they are British or not British. So you could have a British person who's gone to live overseas for a few years and coming back they would be counted, in theory, at least in the data, as a migrant. There are other definitions though that are very useful for policy. So sometimes people talk about migrants, meaning people who don't have British citizenship, and the value of that is that these are people who are subject to immigration control, effectively that the Home Office is regulating their status. But it's also sometimes quite useful not to look at whether someone's a citizen now, because of course people can change their citizenship, and many migrants to the UK do become British citizens. So it can be useful to look at whether someone has migrated in the past. The standard definition for that is whether someone is born abroad. But now we've got all these exciting new data sets from administrative data, and so there's a new definition that's creeping in and being used a lot, which is someone who was a non-citizen at the time they registered for their National Insurance Number, regardless of whether they've subsequently become a British citizen. So it's a bit confusing sometimes for the external user, because for various reasons, we have to have all of these different definitions. You just have to know which one you're looking at at any point in time.    MILES FLETCHER  But the basic headline definition, as far as the ONS is concerned -and I guess internationally too because it's important that these figures are comparable- is that it is a person traveling from one country to another for a period of 12 months.   MADELEINE SUMPTION  That's right  MILES FLETCHER  And I guess that is something that is perhaps not widely understood. People understand that migration has a degree of permanence, so they move from one country to another, and yet you can be a migrant in quite a sort of transient way.   MADELEINE SUMPTION  That's right, we have short term migrants as well. So we have a lot of people who come to this country to do seasonal work. For example, they spend up to six months in the country. Then you have people who are long term migrants by the ONS definition and they may spend two to three years here, for example, if they're a worker or an international student. So you're right. I think in people's minds, often when they think about who is a migrant and who comes to mind, they will typically think of someone who is moving permanently. But actually a lot of migrants to the UK only stay for a couple of years.   MILES FLETCHER And none of these people, when it comes to measuring them, none of these people arrive Paddington Bear style with labels around their necks saying “I am a migrant”. The ONS in measuring migration has to classify whether these people qualify or not.   MADELEINE SUMPTION  That's true, and that is very tricky. And it's something I think the non-technical user of the statistics finds it difficult to appreciate quite how hard it is for ONS to work out who is a migrant or not. Because we have millions of people crossing our borders every year, most of them not migrants. We have tourists or people who come in to visit family members. There are all sorts of people and reasons why those people come and go, so ONS is really looking for the needle in the haystack, and a relatively small share of people who are crossing the borders are actually migrating.   MILES FLETCHER  Well, that seems a good moment to bring in the person who is in charge of finding that needle in the haystack statistically. Mary, tell us how we approach this task. Perhaps start off by explaining how we used to do it. MARY GREGORY  Previously we used a survey called the International Passenger Survey, and there we would ask a sample of people as they came into the country, or as they left the country, what their intentions were, and we'd be able to provide very early estimates based on people's intentions to stay or to leave.   MILES FLETCHER  This is people at airports and other ports of entry, ferry ports, for example, simply approaching people as they wander along the corridors, almost in a random sort of way.   MARY GREGORY  Exactly that, you might have seen them. If you have travelled through an airport you may have seen a desk that sometimes says Office for National Statistics. And there would sometimes be people there with very carefully scheduled timetables to make sure that we collect a good cross section of people.   MILES FLETCHER  So the International Passenger Survey is essentially a big sample survey. Nothing wrong with that, and yet, the number of people being stopped at airports who did actually identify themselves as being migrants was quite small, and that made for some very broad-brush estimates didn't it?   MARY GREGORY  Yes, as you can imagine, people travel through airports or ports for many different reasons, and a lot of those people traveling will be traveling for a holiday or business or to visit family. And so the proportion of those people who are actually going to become residents or leaving for more than 12 months is very small, which makes it really difficult to pick up a good sample of those people.   MILES FLETCHER  And because it's fair to say the International Passenger Survey was never set up to measure migration in the first place, and that was something ONS found itself pointing out for a long, long time before things actually changed. MARY GREGORY  For a number of years we made clear that it was being stretched beyond its original purpose, and that it was the best measure we had at the time but now we think we can do better. And I think one other really important aspect of that is understanding that the survey was asking about people's intentions, and intentions don't always match reality of what we then see.   MILES FLETCHER  Because you might arrive as a student, end up working, settling, starting a family...   MARY GREGORY  Yes. Or you might find that you've arrived planning to stay for a year and then change your mind and you've left again. So it could go in either direction.   MILES FLETCHER  So the case for change was strong. What has changed? How is migration measured now?   MARY GREGORY  So now we have a variety of different ways to measure depending on the nationality of the people arriving. So for anybody from outside the EU, we have good data around visas from the Home Office, so we can use that to understand who is coming and what their reasons for travel are, and we can come on to that a little bit later. For people within the EU, that was a bit more difficult because prior to exiting the EU nobody needed a visa. And so at the moment, we use administrative data, so that's data collected for other purposes, and we use data from DWP, so the Department for Work and Pensions, to understand who has come into the country and who is staying in the country for more than 12 months. And for British nationals, we still, at the moment, use the International Passenger Survey, but we hope to change that very soon.   MILES FLETCHER  And essentially, the last use of the IPS, as far as migration is concerned, is to capture British passport holders leaving the country because nobody else is counting them out.   MARY GREGORY  That's right, and it's actually just stopped collecting that data. So we will move to the new methods very soon.   MILES FLETCHER  Okay, so how successful would you say this shift has been?   MARY GREGORY  I think we've definitely improved the data we can provide. It's a better reflection of people's behaviours. We know that because we've compared the different methods and looked against the census and how the population has changed there. But there are also other advantages as well. So we can now look a lot more at why people have come to the UK, or which are the people who are leaving, so we know more about the reasons for migration as well.   MILES FLETCHER  Madeleine, you run what's recognized as one of the leading think tanks in this area. How much of an improvement is the current system?   MADELEINE SUMPTION  I think the data that we have, particularly on non EU citizens, is much better than it was in the past. Just to give an example, back in the early 2010s there was a big political debate about what the right level of net migration should be, and the government had a target of getting net migration down to under 100,000 from where it was. It was around 200 to 300 thousand at the time. So of course, the biggest question was, how do we do this? And the problem was that, based on those old data, we had no idea how many students were leaving the country. If someone came on a student visa we maybe caught them coming in but there were various problems. We just couldn't measure accurately enough the students going out. And so this most basic of questions, how can the government meet its net migration target, was not possible to answer with the data. Fast forward now ten years, and at least for non EU citizens, we now have pretty detailed data so we can say, okay, this number of people came in on student visas, this share of them left, that share is actually a bit lower than people were expecting. So those are quite interesting data. At the moment we can do the same for work visas, family members, refugees - so that's a dramatic improvement. There's still work to do I think on EU citizens. The ONS is measuring quite high levels of both EU immigration and emigration, of people who don't seem to be coming on visas and probably have a status from before Brexit, but we don't have a great sense of that. And as Mary mentioned, we currently don't really have any data on British citizens migrating, so that will need to be fixed. But yeah, I think the overall picture on immigration and emigration is much better than it was. Separately in the system, there are some challenges, let's say, with the surveys that give us data on the population of people in the country, their characteristics and so forth. And that, I think, has deteriorated a little but hopefully will come back on track.   MILES FLETCHER  And bedding in the new system has brought about the need for some pretty big revisions. And that, of course, brings challenges doesn't it. Around confidence in the numbers when you have to revise by several hundred thousand the number of people that have been classified as migrants. And you get these sort of headlines about the ONS, you know, missing the population of Cambridge or wherever it was. But it wasn't a question of missing people as such, was it? It was just getting better data to understand which of the people coming and leaving should actually be classified as a migrant.    MADELEINE SUMPTION  Yes. There were a number of issues there. There were a couple of cases where it was a case of missing people. There were some Ukrainians, for example, that got lost in the data. But that was a relatively small part of the overall revisions. Mostly, I think there's a challenge, and this challenge is not going to go away entirely but I think that the situation is improving, that when people's behaviour is changing the ONS still has to make assumptions about how long people are going to stay if they want to produce the data quickly. And so when you have a big policy change, you've got new groups of migrants coming in who don't necessarily behave, you know, leave and arrive after the same amounts of time as the previous groups of people who came in. Then you're more likely to have some revisions. And that's one of the things we've seen over the past few years.   MILES FLETCHER  Let's trace the story of migration, if we can, just over the course of this century so far because it's been one of, if not the biggest, political stories. And you might argue, one of the factors that has determined the course of political events in this country. Obviously the ONS is not a political organization, but its figures do tend to have an enormous influence in that direction. Migration really became a big issue in that sense around about the early part of the 21st century when countries were joining the EU from the old Eastern Bloc. And suddenly there was a perception not only that there were large numbers of people arriving as a result of EU enlargement, but that the ONS was struggling to actually keep track of them as well.   MADELEINE SUMPTION  Yeah. I mean, I would say that the increase in migration was even a few years earlier than that. The EU enlargement was one of the biggest events in migration in the last 30 years but there had already been a bit of an uptick in non EU migration, even from the late 1990s, and that is something that we saw across a number of countries. So the UK has been a major destination country, and is, if you look at comparable European countries, towards the top of the pack. But interestingly, we've seen some broadly similar trends in quite a lot of high income countries towards higher levels of migration. And that, of course, you know, as you've said, it's made migration much more salient in the political debate, and it's greatly increased the demand for accurate migration stats. And not just stats on the overall numbers, which of course are important, but really understanding who is coming to the UK. You know, what kinds of visas are they on? What do we know about their characteristics, their nationalities? How do they do when they get here...So I think that the demand for good migration statistics is just much higher than it was at a time when the UK experienced relatively limited migration.   MILES FLETCHER  It's arguable that it was indeed rising EU migration that actually led to the events that led to Brexit. What has changed in terms of migration flows because of Brexit?   MADELEINE SUMPTION  Well, the changes have been really big actually. I mean before Brexit quite a substantial share of all migration was from EU countries. After the referendum, even before the UK left the EU but after the referendum vote had been taken, there was already a decline in EU migration for a host of reasons including the exchange rate and so forth. So in some ways Brexit did what it was expected to do in reducing EU migration to the UK, because when free movement ended we saw quite a dramatic decrease in EU migration. And net migration from EU countries is now actually negative. So we've got the EU citizen population in the UK shrinking. But what was unexpected about Brexit was that then there was quite a big increase in non EU migration for various reasons. So partly policy liberalisations that at the time didn't necessarily look like a massive liberalization, but I think that the take up from migrants was much more enthusiastic than perhaps the government had expected. Lots of things came together. More international students, more workers, the war in Ukraine of course and lots of Ukrainians coming to the UK. And all of those came together at the same time and meant that we then ended up unexpectedly with these record high levels of net migration, peaking at just over 900,000 between 2022 and 2023. And now, of course, the numbers are coming right down again. So we had a record increase, we've then had a record decline to back to what are actually still pretty high levels of over 400,000. So we've really been on a roller coaster ride in terms of the migration patterns in the last few years.   MILES FLETCHER  Yes, and statistically the contrast between what's happened recently is that these migrants have become much more conspicuous and much more measurable because they're being covered by visa data, whereas previously, the EU migrants in the early part of the century weren't actually picked up until the until the census in 2011 were they?   MADELEINE SUMPTION  Yes and my hope is that because we're now measuring migration using visa data, when we get to the next census hopefully it will mean that those revisions - especially given that we'll have planned revisions over the next few years to the data - the hope is that that will mean we won't need such big revisions at the next census because we will have had a slightly more accurate measure between the censuses.   MILES FLETCHER  And I guess the three elements in this recent wave of migration that have attracted particular attention, yes, people have come to work and people have come to study as previously, but in this latest wave, people were bringing more of their dependents with them weren't they? Perhaps because they were coming from further afield?   MADELEINE SUMPTION  There's a bit of a puzzle about precisely why that increase in the number of dependents happened when I think it seems like there were probably two main factors. You've got international students bringing family members. We saw a shift in the countries as you mentioned, the countries that students were coming from. A lot more students from Nigeria, and they're more likely to come with their family members. We also saw a really big increase in the number of people coming to the UK as care workers after the government opened up a route for care workers. And so in one year alone, in 2023, there were visas issued to over 100,000 care workers, and they brought more than 100,000 family members with them, partners and children, that is. But that's now changing, because in response to these changes the government then introduced restrictions on the migration of family members, specifically of care workers and international students. So we've seen over the last year that fewer people are now bringing their family members with them.   MILES FLETCHER  Interesting example of better data enabling a policy response in that sense.   MADELEINE SUMPTION  Yes, and I think it has been very helpful that we've had these data on dependents. Ten years ago we would not necessarily have known. We would have seen that migration was high but it wouldn't have been very easy to distinguish whether people were coming as the partner of an international student or the partner of a health and care worker and now we do have those figures which is incredibly helpful for the policy debate.   MILES FLETCHER  Oh, Mary, one thing we haven't spoken about so far is the impact of COVID. How did the system cope with that period? In measuring the negligible flows to start with, but then the turning on the taps again as things returned to normal...   MARY GREGORY  I think in terms of measuring the statistics it was a massive challenge because the International Passenger Survey stopped and then it was agreed that it wouldn't restart measuring migration, and it actually accelerated our progress to what is now a better measure, but it happened under very difficult circumstances. So we very quickly moved to using administrative data. So data collected by government already to help us measure. And of course there was so much going on then that added to the challenge. Exiting the EU, changes to the immigration system etc. So it was really important we were very careful about how we make sure we understood what had caused the changes and how we measured it really accurately.   MILES FLETCHER  There was indeed another test of the credibility of the ONS migration estimates when it was announced that a very large number of people had applied for settled status just as we were about to leave. These are EU citizens applying for settled status in the UK just as we're about to leave the EU. How do we reconcile those two very different estimates, because a lot of people use them to suggest that there were far more people here than you've been telling us for all these years.   MARY GREGORY  What we can do is we can look at the data sources available to us. The census is a really valuable source in that respect because it gives us the most comprehensive view of the whole population for England and Wales, done by ONS. Obviously, Scotland and Northern Ireland are done by their own statistical offices but we can look at that to get a much better understanding of the full components of the population. But of course, it was really difficult. When there was free movement across the EU we wouldn't know for sure how many people have come and how many people have left. And that's actually become a little bit easier in terms of a statistical viewpoint, because now people do need to have visas in order to travel unless they've got settled status already.   MILES FLETCHER  The new system has been bedding in these last couple of years, and you've had the unenviable job of announcing some pretty large revisions to the figures. Have things settled down now?    MARY GREGORY  So I think we've made really good progress on people traveling from outside the EU as Madeleine already referred to. We know a lot more about them. We're more confident in that aspect, and we would hope therefore, that the revisions in future will be much lower in scale. There will always be some revisions because we are making assumptions about people. Just to pause on that for a second. We publish data five months after the reference period, but obviously it's 12 months before somebody meets the definition of being a migrant. So we have to make some assumptions about who will stay and who won't, but those are relatively small and should be small in terms of revisions. So I think with non EU numbers we have made really good progress and that is the largest part of the picture. So just to put that in perspective, in terms of immigration just over four in five people immigrating in in our latest data are from outside the EU, so that's positive. Where we do have more work to do is those people coming from within the EU and British nationals, and we've got plans to develop the methods for both of those so we will see revisions coming up in both of those areas. We will put out more information in the autumn about the progress we've made, and if they're ready and we think the quality is good enough, we will implement those methods in November. Otherwise, we'll wait until the following publication because for us it's really important that when we do this we do it properly.   MILES FLETCHER  And important for everybody to remember that the ONS, in the job it does, can only make the best of the information that's made available to it at any given time.    MARY GREGORY  Yes absolutely. And I think especially with the British nationals where there are a lot of challenges. Because, of course, if you're a British national you come and go as you please. The other things that we are looking to improve are going to be less significant in terms of the headline numbers but are also really valuable. So if we can change the methods for EU, for example, we should be able to do more on people's reason for migration. And we also hope to do more on breaking down those from outside the EU, to understand a bit more detail about how long people are staying and if they change visas, that kind of thing.   MILES FLETCHER  Mary, thank you very much. That seems a good moment to bring in Hannah.   Hannah, then, from what you've heard, as someone who's in the business of tackling misinformation and ensuring that debates are properly understood, what is your assessment of how useful, how reliable, the ONS migration data are?   HANNAH SMITH  Now as we've been hearing from Madeleine there's been some significant improvements in the way that the data is collected and published. I think another thing that can give people confidence is how transparent the ONS has been with not only the strengths of the data, but also the limitations and the work they're doing surrounding ongoing development with that. I think that's absolutely key when we're talking about access to good information –transparency- understanding what the data can tell us and what the data can't tell us, and what the ONS is looking to do to change that. I think ultimately this is, as we've been hearing, a really complex issue, and trying to reconcile that with the fact that it's of massive public interest. And, as Madeline has been saying, someone who is not a technical user of the statistics, it's really important for someone like that to be able to understand these issues in a straightforward way, and trying to find that balance between getting the right level of detail that can be understandable for a general user is difficult. But I think the ONS has been really open about the challenges with that, and this conflict between the idea of timeliness and completeness of data, as Mary was just saying, we don't have complete data at the moment that the first statistics are published, but obviously the alternative is just to wait a really long time until that full data is available. So I think trying to strike that balance is also key, and something that, like I say, just being transparent about that is the best way to approach it.   MILES FLETCHER  In your work for Full Fact, what do you come across as the major misuses of migration figures, the deliberate misunderstanding of migration figures. And how well equipped Are you to combat those?  HANNAH SMITH  It's hard to know how much of it is deliberate misuse of migration figures, and how much of it is, as you say, due to just misunderstanding the data. I think there are obviously some things that we don't know, some information gaps. So, for example, the scale of illegal migration is something that's perhaps a bit harder to capture, just by the very nature of it. That's something that we found is a really common theme in the things that we're fact checking. You know, we've seen surveys that show that a quite significant proportion of the public thinks that the data shows that more people are entering the country illegally than legally. We fact check politicians who make similar claims. So we know this bad information does cause real harm, and I think that's why the information that the ONS is publishing is really, really important for reasoned debate, and just having that information available is the first step to help counter the bad information that's out there. MILES FLETCHER  You mentioned illegal immigration or undocumented migration, that by its very nature is a tricky one, because it's difficult to accurately measure isn't it, and to come up with a robust estimate that can counter exaggerated claims.   HANNAH SMITH  Yeah, of course. And we know that some of the people who are arriving in the country, either undocumented or illegally are captured in the data. So for example, the data we have on small boat arrivals, but it is ultimately, like you say, hard to estimate. And I think similarly to what Madeleine was saying earlier about the different definitions of what constitutes a migrant. Different people will have different views or different understandings of what constitutes illegal migration. So that's another thing that we have to bear in mind when we're talking about this issue.   MILES FLETCHER  And do you feel you've got the tools to effectively combat the worst excesses of the Wild West that social media often is?   HANNAH SMITH  Yes we do work with social media companies. So we have a partnership with Meta which allows us to directly rate misleading content that we see on their platforms. And we definitely do see a lot of content specifically related to migration which thanks to that partnership we are able to have influence on. But at Full Fact I think we're always calling for improvements in how better to combat misinformation, not only in this space, but just generally. So media literacy, for example, we think is a really vital step that's needed to ensure people are equipped so that they can spot what's fact and what's fiction. And we've been making a lot of recommendations in what can be done to improve media literacy to meet the public's needs. We also think that legislation needs to be strengthened to tackle this kind of misinformation and other sorts of harmful misinformation that crop up online. So yeah, we do have a lot of tools at our disposal, but we think that the information environment and the regulations surrounding it could always be strengthened.   MILES FLETCHER  That's interesting. And what sort of areas do you think it could specifically be strengthened? As far as the production of statistics are concerned?   HANNAH SMITH  I think, as I say, transparency and accessibility is key. I think perhaps trying to anticipate where misunderstandings could crop up. A lot of the work we do, or an approach that we can take with fact checking, is something we call pre bunking, which is trying to look at what topics are resonating with the public, what things we think might crop up, and then producing content that puts the correct information out there. Ideally, trying to get ahead of the bad information. I don't know if I'm going to butcher this saying, but a lie gets halfway around the world before the truth had time to put his boots on. I think that pre bunking is an effort to try and reverse that. And I think there's a parallel there with anticipating, as producers of information, where the misunderstandings might be likely to fall, and putting content warnings on or health warnings as prominently as possible, and also making sure that the people that are using the information, whether that's the media, politicians, other people, are aware of potential pitfalls to try and minimize the risk of that spreading to a wider audience.   MILES FLETCHER  Survey information we have from our own sources - the public confidence in official statistics survey - suggests that people who have heard of the ONS tend to recognize the fact that it is independent, that we are not subject to political control, and therefore you might think people should have confidence in the figures. Is that corroborated by your experience?   HANNAH SMITH  That's really interesting. I'm not entirely sure. I think from a fundamental point of view, I think trust in organizations like the ONS, knowing that you're getting impartial evidence, knowing that you're getting unbiased information that's been put through the most robust scrutiny that it can be, can only be a helpful thing. We know that trust in politics is at a very low level, so having those impartial producers of information that we know aren't subject to any political control or affiliation, I think can only be beneficial for that.   MILES FLETCHER  Madeleine, this is where the National Statistician's Advisory Panel on Migration comes in, the body that you chair. Can you just tell us a little about its work? What its role is?   MADELEINE SUMPTION  Yes. So this is a new body that will advise the ONS on migration statistics. Obviously, the ONS migration teams have been soliciting expert advice in various ways for several years. I know this because I've been part of that process as well, but the arrangements are being formalized now, actually building on the model that I think has worked quite well in some other areas of migration statistics, like labour market data, for example, to have a panel of independent experts who help advise on things like whether the statistics are really answering the questions that users have. Obviously ONS has a lot of excellent statisticians, but they're not expected to be deep in the weeds of the policy debate and really sort of understanding exactly how people want to use the data and so forth. So the idea of this panel is to have some of that independent voice to help ONS shape its vision of what kinds of data it can produce. How can it make them more relevant and accessible to users, that kind of thing?   MILES FLETCHER  And I guess when you ask most people whether they think migration does have a role to play, particularly in modern economies, answering that question depends on having good data, having data that meets the needs of experts in economics and so forth. So we can see whether indeed, migration is having a positive economic benefit.    MADELEINE SUMPTION  Yes there are lots of things that the data are needed for. So looking at the impacts on the economy is one of them that the Office of Budget Responsibility, for example, uses the migration data when it's making its forecast of how much money there is effectively. So you know, how big is the population? What are people likely to be paying in tax? What are we likely to be spending in addition on services? Because we have more migrants, more people in the population. So it's important for the financial impacts. It's important for planning public services. How many school age kids are we going to have? How's that changing? What do we need to do to plan school places? And yeah, then it's important for the broader policy debate as well, understanding different categories of migration, what should the Home Office do? What should other government departments do, and thinking about how to respond to the impacts of migration.   MILES FLETCHER  Yeah. And you can't calculate GDP per head of population until you know how many heads there are, to reduce it to its most simple terms.   MADELEINE SUMPTION  Indeed. Yep. And that's been one of the challenges. There are more challenges along those lines, when thinking about the impacts of migration, we're getting a lot more administrative data, so data from basically the records of different government departments and agencies around the country, that will tell us things like how many migrants are claiming benefits, or how many migrants are imprisoned, or any number of things. And it's really important that if you want to be able to interpret those statistics, you really must have a good idea of how many migrants are from different countries, different parts of the world, are in the country in the first place. Otherwise you might make your calculations wrong. And I think there is still more work to be done in that area, in particular looking at population. We've been talking mostly about migration in and out of the country. There's still a fair amount more to be done on making sure that we have really accurate statistics on the number of people who are here at any one point in time.   MILES FLETCHER  Mary, finally from you then, do you support that good progress has been made, but important steps are still to come?   MARY GREGORY  I think so. I mean, there's always improvements that can be made. No matter how good we get, we will always want to do better. But I think also it's such a privilege, but a huge responsibility, to work on something so important, and we don't take that lightly in ONS. We know that these numbers make a difference to so many people, and as Madelene said, the number of people in the country is a really important number, but so often the thing driving that is the migration figure. So without the really good migration data, we don't have the really good population data, and so we will keep working on that together as well as we can.   MILES FLETCHER  And on that positive note we must come to the end of this podcast. Thanks to you, Mary Madeleine and Hannah, for your time today, and as always, thanks to you at home for listening.   You can subscribe to future episodes of Statistically Speaking on Spotify, Apple podcasts and all the other major podcast platforms. You can also follow us on X, previously known as Twitter, via the @ONSFocus feed.   I am Miles Fletcher, and from myself and producer Steve Milne, until next time, goodbye.    ENDS  

Rachel Reeves Achieves More Growth, which Could Lead to Yet more Growth! #Podcast UK government borrowing rose by more than expected last month, adding to the pressure on the Chancellor, Rachel Reeves. Analysts say it is increasingly likely that the chancellor will have to raise taxes at the Budget in the autumn, after the government reversed cuts to benefits that had been aimed at saving billions of pounds. The latest borrowing figure was the second-highest June figure since monthly records began in 1993, the ONS added, behind only June 2020, which was heavily affected by the pandemic. MICROCAP CO'S COVERED TODAY: EENERGY #EAAS FONIX MOBILE #FNX HVIVO #HVO NEXTEQ #NXQ SPACEANDPEOPLE #SAL THEWORKS  #WRKS  ***** About The SharePickers Investment Club ***** The SharePickers Investment Club employs a unique, systematic method to uncover small, profitable companies on the London Stock Exchange.  Each potential investment undergoes comprehensive analysis and is evaluated against 15 crucial financial metrics.  This fact-based, quantitative approach allows us to pinpoint high-potential growth businesses and deliver consistent results, bypassing the hype and focusing on the numbers.  *****MY BOOK ***** How to Become a MicroCap Millionaire - A 3 Step Strategy for Stock Market Success  Is now on sale here: https://www.sharepickers.com/how-to-become-a-microcap-millionaire-3-step-strategy/ !!!IF YOU BUY THE BOOK YOU CAN GET 25% OFF MEMBERSHIP TO THE SHAREPICKERS INVESTMENT CLUB!!! The book is £15.39 on Amazon you can get £49.75 back. HOW? If you buy a copy of the book, then like it enough to leave a 5 star rating & write a positive review, you can get yearly membership to the SharePickers Investment Club for just £149.25!!! THIS IS £2.87 WEEK - LESS THAN: HALF A PINT OF BEER A BATTERED JUMBO SAUSAGE FROM THE CHIPPY HALF THE AMOUNT A PERSON SPENDS ON CHOCOLATE ONE FEEDS YOUR MIND THE OTHERS FEEDS YOUR BELLY. —---------------------------------------------------------------------- In this podcast I cover the Microcap News to see if they're good enough to be added to the MicroCap League. The UK's first MicroCap League where 100's of small businesses are analysed and scored in relation to their growth, value, health, efficiency, momentum & potential. The companies that score the highest are added to the MicroCap League and possess the best risk / reward profile. —---------------------------------------------------------------------- If you regularly listen to this podcast and enjoy its output please consider giving it a 5 star rating and review - that way more people will find it. Thank you.

Reaksie op die Minister van Hoër Onderwys en Opleiding se afdanking. Wie is die nuwe minister, Buti Manamela? Die seëvierende Junior Bokke trots terugverwelkom. Vandag, op Wêreld Breindag, is die vinnige toename in demensie-gevalle onder die soeklig. Ons praat met 'n neuroloog.

Send us a textSpreuke 25:28 'n Stad sonder 'n muur om hom te beskerm, so weerloos is 'n mens as hy nie selfbeheersing het nie. Het jou emosies al ooit handuit geruk? Jou antwoord is waarskynlik: Maar alte seker! Jy weet hoe dit werk – iets wat jy voel, hetsy goed of sleg, gelukkig of ongelukkig, oorheers jou gesonde verstand … en net daar neem jy ‘n verkeerde besluit; jy sê, of doen iets, waaroor jy later baie spyt is!Ons kan nooit ons emosies ignoreer nie. Hulle is 'n groot deel van wie ons as mense is. Stel jou voor wat 'n onvervulde lewe sou dit gewees het...as jy geen emosie gehad het nie en net op logika en rede moes staatmaak om jou deur die lewe te kry …  Ja, ons emosies is 'n goeie ding, so laat ons dit nooit ontken nie ... maar my vriend, hulle kan ons in groot tameletjies laat beland, nie waar nie? En dit is waar selfbeheersing inkom. Dit is waarom ons in die grootword proses, moet leer om ons emosies en instinktiewe reaksies, met redelikheid, vriendelikheid, en met inagneming van ander, te beheer.Sommige mense leer daardie les goed. Dit lyk selfs of dit vir hulle redelik maklik is. Vir ander, soos ek byvoorbeeld, is dit 'n lewenslange proses. Waar jy ook al op die spektrum van emosionele intelligensie is, luister na:Spreuke 25:28 'n Stad sonder 'n muur om hom te beskerm, so weerloos is 'n mens as hy nie selfbeheersing het nie.Met ander woorde, in die afwesigheid van selfbeheersing, sal jou lewe voortdurend gepootjie word deur die gevolge van jou foute. Iemand het eenkeer hierdie wyse woorde gesê: moet nooit antwoord wanneer jy kwaad is nie, moet nooit 'n belofte maak wanneer jy uitbundig gelukkig is nie en moet nooit 'n belangrike besluit neem wanneer jy hartseer is nie.Want … mense wat hulself nie kan beheer nie, is soos stede sonder mure om hulle te beskerm.Dit is God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Ons dink na oor die triniteit. 

Ons dink die week na oor God en hoe Hy Homself aan die mensdom geopenbaard het. 

Ons sal nie bo ons kragte versoek word nie. God is daar.

Send us a textMatteus 7:1-2 Moenie oordeel nie, sodat oor julle nie geoordeel word nie; met dieselfde oordeel waarmee julle oor ander oordeel, sal oor julle geoordeel word, en met dieselfde maat waarmee julle vir ander meet, sal vir julle gemeet word. Ek hou nie daarvan om foute te maak nie – maar ek moet ruiterlik erken dat ek soms oordeelsfoute maak en dinge instinktief sê of doen waaroor ek later spyt is. Maar jy weet seker nou presies waarvan ek praat, want ons maak almal foute, Nè!En hier is ons strategie: Wanneer ons 'n fout maak, probeer ons dit óf ignoreer, óf dit te regverdig deur een of ander verskoning te maak om onsself uit die pekel te kry. Maar o wee, staan terug, want wanneer iemand anders 'n fout maak wat ons lewe beïnvloed, of ons selfs net so effens verontrief, dán reageer ons! Dan trek ons los – óf deur ‘n stortvloed van woorde, óf deur ons harte teenoor hulle te verhard.Soos iemand eenkeer gesê het, ons is baie goeie prokureurs as dit by ons eie foute kom; maar ons is baie ongenadige regters wanneer dit by die foute van ander kom!Hoekom is dit so? Hoekom is dit dat wanneer iemand anders iets verkeerd doen, ons ‘vergeet' dat hulle ook mense is? Ons dink nie daaraan dat hulle ook ‘dinge' in hul lewens aan die gang het nie. Waarom dink ons nie vir ‘n oomblik aan die seerkry, stres, letsels of gebreke wat hulle gedrag kan beïnvloed nie? Waarom nie?Jesus het in die Bergpredikasie, 'n baie sterk waarskuwing oor hierdie einste ding gegee:Matteus 7:1-2 Moenie oordeel nie, sodat oor julle nie geoordeel word nie; met dieselfde oordeel waarmee julle oor ander oordeel, sal oor julle geoordeel word, en met dieselfde maat waarmee julle vir ander meet, sal vir julle gemeet word. Kyk mooi na die kern van hierdie streng waarskuwing. God sal jou op dieselfde manier behandel as wat jy ander behandel.Hou op om ander mense sonder genade te oordeel. Dit is God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Barbara zit in Thailand, Gijsje is herstellende van haar borstverkleining, dus deze week is onze co-host: actrice Anniek Pheifer. Anniek heeft net haar propedeuse gehaald van de lerarenopleiding geschiedenis en heeft wat moeite om in vakantiestand te komen. Femke moet even keihard knallen, want haar vakantie begint over een paar dagen. Ze voelt zich overigens vrij belabberd, want is net begonnen aan een hogere dosis Ozempic. We reten monogamie, want wat is het toch lekker om daarover te praten. Anniek pleit voor Monogamie plus amendementen. Dus geen polyamorie, geen vrije relatie, maar heel soms een klein zijpaadje. Ons fragment gaat over docent worden en hoeveel je daarvoor moet oefenen. Anniek is bang dat ze zo ongeveer met pensioen gaat als ze het vak eindelijk in de vingers heeft, maar oh, wat vindt ze het geweldig om voor de klas te staan (en wij denken dat ze een fantastische docent gaat zijn!). Onze gast is Judith Akkerman die de glossy Alle Mooie Borsten lanceerde. Te verkrijgen via allemooieborsten.comSunny CarsKrijg 25 euro korting op je volgende huurauto van Sunny Cars. Ga naar sunnycars.nl/saarpodcast of gebruik de kortingscode SUNNYSAAR. De actiecode is te gebruiken tm 30 september 2025.BOL/KoboOok eindeloos doorlezen? Probeer Kobo Plus nu 30 dagen gratis via bol. Ga naar bol.com/koboplus. ZespriKiezen voor Zespri kiwi's, dat is kiezen voor echt. Wil je nog meer leren over echte voeding en welke gezondheidsvoordelen deze met zich meebrengen? Lees er alles over op (nieuwe pagina) en download het e-book van Zespri. Ga naar Zespri.comAdverteren?Wil je adverteren in deze podcast? Stuur dan een mailtje naar adverteren@bienmedia.nl.

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35

FlySafair tref voorsorgmaatreels ter voorbereiding van 'n dreigende staking deur vlieëniers. Ons praat met die medevoorsitter van die groep van vooraanstaande persone, dr. Roelf Meyer, wat die Nasionale Dialoog sal lei. Op Mandela-dag praat ons oor leierskap, spesifiek verantwoordelike leierskap, of die gebrek daaraan.

Jayden-Lee Meek se vermeende moordenaar gaan vandag om borgtog aansoek doen. Defend South Africa eis die president se bedanking. Ons praat met ‘n kenner oor nabygeleë ruimtevoorwerpe wat 'n gevaar vir die aarde kan inhou. 'n Teaterproduksie oor mensehandel en misdaadsindikate het feesgangers by die Vrystaat Kunstefees aan die praat.

Roelf Meyer en professor Tinyiko Maluleke is aangestel as die voorsitters van die beplande Nasionale Dialoog. Die Verenigde Nasies veroordeel Israel se lugaanvalle op Sirië. Ons praat met Vrystaat Landbou oor veiligheid aan die Lesotho-grens. Kaderontplooiing kom onder die soeklig. 'n Nuusveteraan praat oor SABC NUUS se 75ste herdenking.

On this week's episode of The Debrief, MT's editorial team discusses what can be done to boost business optimism and how groupthink can sabotage your transformation agenda.If the first quarter's GDP figures briefly put a spring in Rachel Reeves' step, this boost would have been short-lived, while we can only assume she had regained the standard-issue world-weary tread of a put-upon chancellor by the time the ONS's latest monthly estimate rolled around. The 0.7% increase in GDP that raised spirits early in the year gave way to projections of virtually flat growth in the second quarter, while the most recent data for May showed a surprise – if small – contraction of 0.1% (let's not even mention the latest inflation figures). But Downing Street aren't the only ones feeling under siege. With sentiment among businesses faring scarcely better, we asked our community of CEOs what's needed to boost optimism.It's common to strive towards consensus, but at what point do organisations become echo chambers, where new ideas quickly lose steam under the collective weight of conformity - if they ever even see the light of day? And as businesses face the need to rapidly evolve to meet new realities, what implications does it have for transformations if teams are governed by common assumptions, shared notions of ‘best practice' and attachment to what's come before? Data Impact author Ritavan's own view is clear: groupthink is the “silent killer of transformation”. We discuss his argument.Credits:Presenters: Antonia Garrett Peel and Éilis CroninProducer: Inga MarsdenArtwork: David RobinsonLinks: https://www.managementtoday.co.uk/mt-asks-against-backdrop-economic-headwinds-boost-business-optimism/opinion-and-analysis/article/1925050https://www.managementtoday.co.uk/groupthink-enemy-transformation/opinion-and-analysis/article/1924413 Hosted on Acast. See acast.com/privacy for more information.

De machines rukken op! Of het nou gaat om de smartphone, kunstmatige intelligentie, of dieper nog: de manier waarop we onbewust naar de wereld kijken. Ons hele leven – en zelfs ons mensbeeld – is beïnvloed door de machine. Zijn wij de machines nog de baas, of is het inmiddels andersom? Roderick Nieuwenhuis is daarom terug in De Ongelooflijke. Hij is journalist, historicus en schreef het boek 'Mens en machine'. Het mooie aan Roderick is: hij heeft altijd goede verhalen – én dingen die je nog niet wist. In deze aflevering struinen we door de geschiedenis en literatuur, langs grote denkers, kunstenaars en kantelmomenten. Roderick knoopt het allemaal aan elkaar en eindigt bij een cruciale vraag: wat doet techniek met onze ziel? En hoe gaan we daar goed mee om? Roderick Nieuwenhuis is naast schrijver ook docent journalistiek aan Hogeschool Windesheim. David Boogerd sprak hem samen met onze vaste gast, theoloog Stefan Paas, hoogleraar aan de VU in Amsterdam en de Theologische Universiteit Utrecht.

“We want to make sure that nurses, have opportunities both in our local communities as well as international communities, to engage in courageous dialog with others who may think or look different than we do and whose culture or language may also be different. The difference is what brings us together and allows us to have more of this tapestry of what we are about—ensuring that we advance health for all and that we are able to move forward together,” ONS member Ashley Leak-Bryant, PhD, RN, OCN®, professor at University of North Carolina (UNC) at Chapel Hill, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, chair of the ONS 50th Anniversary Committee, during a conversation about international collaboration in oncology nursing. Burbage spoke with Leak-Bryant, ONS member Kristin Ferguson, DNP, MBA, RN, OCN®, senior director of strategic operations, bone marrow transplant, and cellular therapies at MedStar Georgetown University Hospital, and ONS member and Chief Clinical Officer Erica Fischer-Cartlidge, DNP, RN, AOCNS®, EBP-C, about their experiences working in the global oncology space and how ONS is advancing those efforts. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  ONS Podcast™ ONS 50th anniversary series ONS Voice articles: Bridging Borders and Advancing Oncology's Global Mission Building Collaboration, Education With Oncology Nurses in Malawi Cancer Terms' Negative Associations in African Languages Can Create Communication Barriers for Patients and Clinicians Latest Global Cancer Statistics Underscore the Stark Need to Address Resource-Based Disparities ONS Members Share Resources, Experiences With Philippine Colleagues Clinical Journal of Oncology Nursing articles: Amplifying the Global Impact of Oncology Nursing How Can a Global Experience Enkindle a Passion for Oncology Nursing? Connie Henke Yarbro Oncology Nursing History Center ONS Global Initiatives Joint position statement from ISNCC, MASCC, ONS, AONS, and EONS: Cancer Nursing's Potential to Reduce the Growing Burden of Cancer Across the World Asian Oncology Nursing Society City Cancer Challenge Canadian Association of Nurses in Oncology European Oncology Nursing Society Global Power of Oncology Nursing Health Volunteers Overseas International Society of Nurses in Cancer Care Multinational Association of Supportive Care in Cancer UNC Project Malawi Union for International Cancer Control Email Ashley Leak-Bryant Email Kristin Ferguson Email Erica Fisher-Cartlidge at ONS Global Initiatives To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Leak-Bryant: “My first experience was when I was 21 years old. This was when I was in nursing school at UNC Greensboro. An opportunity came about where I had a chance to go to Honduras, and it was for a one-week service learning cultural immersion experience. And that really gave me my first entree into global health as well as global training. And so, as a first-generation college graduate who had never been out of North Carolina nor had ever flown, it was really an eye-opening experience that has led me now to my current role and passion for global health.” TS 3:24 Leak-Bryant: “In 2018, we had the Malawian delegation come to UNC Chapel Hill. University of North Carolina at Chapel Hill has one of the longest standing collaborations with Malawi, and we call it UNC Project Malawi, and it has been in existence for more than 30 years. … Those nurses and other allied health professionals came to UNC to our cancer center to see how we were making sure that we were engaged in best practices, then how they would be able to take that back to Malawi to make sure that they have what they need as they were opening up a new national cancer Center in Malawi.” TS 7:57 Ferguson: “I have volunteered with ONS at the Asian Pacific Breast Cancer Summit, which was in Indonesia in 2024, and then a few months ago in Singapore. And this is an exciting conference because it draws in nurses from the region, so you end up having five, six, maybe seven countries represented at these conferences, where oncology nurses are very eager to learn, meet one another. And so the teaching that we've provided there has been a combination of lectures and then roundtables where we've strategically placed nurses attending with nurses that are not at their same hospital so that they can connect and share experiences with myself and another ONS member and maybe some other local staff acting as moderators and facilitating conversations.” TS 18:04 Ferguson: “When I was in Tbilisi, Georgia, in 2019, the people there, most of them do not speak English, so they speak their native language Georgian. As I presented, I was wearing a headset, and all of the oncology nurses in the audience were wearing a headset, and I was live translated. What this means is when you're speaking, a translator is sitting in a booth close by and you can actually very quietly hear in your ear he or she quietly translating what you're saying into a language that the nurses can understand. It's actually a bit funny because when you make a joke or ask a question, expecting nods or head shakes, it takes several seconds for the translation to occur. You can get used to a 10-second delay, and you have to pause your speaking and allow actually a little bit more time in presenting if translation services are required.” TS 22:25 Fischer-Cartlidge: “I think that the professional organization role is absolutely critical in how we advance global oncology. Certainly, providing education and helping empower nurses to be more autonomous and equal partners on the care team is a big piece of that. But it's also through forming international partnerships and really elevating the collective voice of nurses in the specialty. This goes a long way in standardizing practices, promoted leadership development among oncology nurses, really across the world. We know that nurses are not seen the same country to country to country on the healthcare team. And so a big part of what we do is try to elevate the importance of what nurses bring to cancer care.” TS 36:14 Fischer-Cartlidge: “I have so many hopes. I hope more opportunities come up for us to raise awareness of this essential role and how we bring a greater spotlight to what nurses are doing across the world for patient care. I hope to see us have more collective global position statements in this space. I hope to see that we have more unified projects across nursing organizations across the world, where we then really can bring our resources and our members together to do great work more effectively and more efficiently. And I think the beginnings of that are happening right up to this point.” TS 41:17  

LES 192Ik heb een functie die God me graag vervullen ziet.Het is je Vaders heilige Wil dat jij Hemzelf compleet maakt, en dat jouw Zelf Zijn heilige Zoon is, voor eeuwig zuiver zoals Hij, uit liefde geschapen en in liefde bewaard, liefde uitbreidend, scheppend in haar naam, voor eeuwig één met God en met jouw Zelf. Maar wat kan zo'n functie betekenen in een wereld vol afgunst, haat en aanval?Daarom heb je een functie in de wereld in haar eigen termen. Want wie kan een taal begrijpen die zijn eenvoudig begrip verre te boven gaat? Vergeving vertegenwoordigt jouw functie hier. Ze is niet Gods schepping, want ze is het middel waarmee onwaarheid ongedaan kan worden gemaakt. En wie zou aan de Hemel vergeving willen schenken? Maar op aarde heb je het middel nodig om illusies los te laten. De schepping wacht louter op jouw terugkeer om te worden erkend, niet om compleet te zijn.Van de schepping valt in deze wereld zelfs geen voorstelling te maken. Ze heeft hier geen betekenis. Vergeving is hetgeen waarmee ze nog het dichtst bij de aarde komen kan. Want in de Hemel ontstaan, heeft ze in het geheel geen vorm. Maar God heeft Iemand geschapen die het vermogen heeft om het totaal vormloze in vorm te vertalen. Wat Hij maakt zijn dromen, maar van een soort zo dicht bij ontwaken, dat het daglicht er al in schijnt, en ogen, die zich al openen, het vreugdevolle schouwspel dat zij bieden aanschouwen.Vergeving beziet mild alles wat onbekend is in de Hemel, ziet het verdwijnen, en laat de wereld achter als een schone, onbeschreven lei waarop het Woord van God de zinloze symbolen die er eerst geschreven stonden, nu vervangen kan. Vergeving is het middel waardoor de angst voor de dood overwonnen wordt, omdat die nu geen hevige aantrekkingskracht meer uitoefent en schuld verdwenen is. Vergeving laat het lichaam zien als wat het is: een eenvoudig leermiddel dat terzijde wordt gelegd wanneer het leren is voltooid, maar hem die leert allerminst verandert.De denkgeest zonder lichaam kan geen vergissingen maken. Hij kan niet denken dat hij sterven zal, of de prooi zal zijn van een genadeloze aanval. Woede wordt onmogelijk en waar blijft dan panische angst? Welke angsten zouden hen nog kunnen bedreigen die de bron van alle aanval, het wezen van leed en de zetel van angst zijn kwijtgeraakt? Alleen vergeving kan de denkgeest ontlasten van de gedachte dat het lichaam zijn thuis is. Alleen vergeving kan de vrede herstellen die God voor Zijn heilige Zoon heeft bestemd. Alleen vergeving kan de Zoon ertoe bewegen weer zijn oog te richten op zijn heiligheid.Wanneer woede verdwenen is, zul je inderdaad ontdekken dat er voor de visie van Christus en de gave van het zien geen offer werd gevraagd, en slechts pijn werd weggenomen van een zieke en gekwelde denkgeest. Is dit onwelkom? Is dit iets om bang voor te zijn? Of is het iets om op te hopen, om dankbaar te begroeten en vol vreugde in ontvangst te nemen? We zijn één en geven daarom niets op. Maar waarlijk is ons alles gegeven door God.Toch hebben we vergeving nodig om te zien dat dit zo is. Zonder haar vriendelijk licht tasten we in het duister rond en gebruiken we ons verstand slechts om onze razernij en aanval te rechtvaardigen. Ons begrip is zo beperkt, dat wat we denken te begrijpen niets anders is dan een uit vergissing voortkomende verwarring. Wij zijn verdwaald in de nevelen van wisselende dromen en angstwekkende gedachten, met onze ogen stijf dichtgeknepen tegen het licht, en onze denkgeest druk bezig met het aanbidden van wat er niet is.Wie kan opnieuw in Christus geboren worden dan hij die ieder die hij ziet, aan wie hij denkt, of die hij zich voorstelt, vergeven heeft? Wie zou bevrijd kunnen worden terwijl hij nog iemand gevangen houdt? Een cipier is niet vrij, want hij zit samen met zijn gevangene vast. Hij moet ervoor zorgen dat die niet ontsnapt en dus brengt hij zijn tijd door met de wacht over hem te houden. De tralies die hem beperken worden de wereld waarin zijn cipier leeft, samen met hem. En van zijn vrijheid hangt de weg naar bevrijding voor hen beiden af.Houd daarom niemand gevangen. Bevrijd in plaats van te binden, want zo word jij bevrijd. De manier is eenvoudig. Telkens wanneer je een steek van woede voelt, besef dan dat je een zwaard boven je eigen hoofd houdt. En het zal vallen of afgewend worden, naargelang je verkiest veroordeeld te worden of vrij te zijn. Op die manier vertegenwoordigt ieder die jou in de verleiding lijkt te brengen om kwaad te worden, jouw verlosser uit de kerker van de dood. En dus ben je hem dank verschuldigd in plaats van pijn.Wees vandaag genadig. De Zoon van God verdient jouw genade. Hij is het die jou vraagt de weg naar de vrijheid nu te aanvaarden. Weiger het hem niet. De Liefde die Zijn Vader hem betoont behoort jou toe. Jouw functie hier op aarde is slechts dat je hem vergeeft, opdat je hem weer als jouw Identiteit aanvaardt. Hij is zoals God hem geschapen heeft. En jij bent wat hij is. Vergeef hem nu zijn zonden en je zult zien dat je één met hem bent.

NESTA EDIÇÃO. Petrobras analisa propostas para serviços de manutenção nas fábricas de fertilizantes do Nordeste. Ministério de Minas e Energia habilita empresa para participar do projeto Poço Transparente, de avaliação do uso de fraturamento hidráulico. ONS pode recomendar retorno do horário de verão para reduzir déficit de potência. Entidades pressionam por aprovação do novo marco do licenciamento ambiental.

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta quarta-feira (09/07/2025): Relator na Câmara do projeto de lei que isenta de Imposto de Renda (IR) quem ganha até R$ 5 mil mensais, o deputado Arthur Lira (PP-AL) afirma que a proposta do governo para compensar essa perda arrecadaria mais do que o necessário. Por isso, parlamentares discutem reduzir a alíquota mínima de IR da alta renda de 10% para 9% ou 8%. Segundo Lira, a isenção de IR para quem ganha até R$ 5 mil resultaria em renúncia de R$ 25,8 bilhões. A cobrança de 10% sobre altas rendas arrecadaria R$ 34 bilhões. A proposta do governo é taxar em até 10% quem ganha R$ 1,2 milhão por ano. A tributação, crescente, começaria a partir de quem ganha R$ 600 mil por ano E mais: Economia: IOF rejeitado pode ser compensado no novo IR Política: PF cumpre mandado de busca na Câmara em investigação de fraude Metrópole: Horário de verão poderá ser necessário neste ano, afirma a ONS Internacional: Trump critica Putin, promete armas para Ucrânia e avalia sanções à Rússia Esporte: Cria da base tira Fluminense do MundialSee omnystudio.com/listener for privacy information.

LES 186De verlossing van de wereld hangt af van mij.Dit is de uitspraak die alle arrogantie eens uit elke denkgeest weg zal nemen. Dit is de gedachte van ware nederigheid, die geen andere functie als de jouwe neemt dan degene die jou gegeven is. Het brengt jouw aanvaarding van een jou toegewezen taak met zich mee, zonder aan te dringen op een andere rol. Het velt geen oordeel over de juiste rol voor jou. Het erkent slechts dat de Wil van God op aarde zowel als in de Hemel is geschied. Het verenigt elke wil op aarde in het hemelse plan om de wereld te verlossen en haar terug te voeren tot de hemelse vrede.Laten we onze functie niet bestrijden. Wij hebben die niet vastgesteld. Ze is niet ons idee. De middelen waarmee ze volmaakt zal worden vervuld, zijn ons gegeven. Het enige wat ons wordt gevraagd is dat wij onze taak in oprechte nederigheid aanvaarden en niet met zelfmisleidende arrogantie ontkennen dat we die waardig zijn. Wat ons te doen gegeven is, daartoe hebben we de kracht. Onze denkgeest is volmaakt toegerust om de taak op zich te nemen die ons is toegewezen door Iemand die ons goed kent.Het idee van vandaag lijkt misschien heel ontnuchterend, totdat je de betekenis ervan ziet. Al wat het zegt is dat jouw Vader Zich jou nog steeds herinnert en je het volmaakte vertrouwen schenkt dat Hij in jou heeft als Zijn Zoon. Het vraagt niet dat je op enigerlei wijze anders bent dan jij bent. Wat zou nederigheid anders kunnen vragen dan dit? En wat zou arrogantie anders kunnen weigeren dan dit? Vandaag zullen we ons niet aan onze opdracht onttrekken met de schoonschijnende reden dat bescheidenheid geweld wordt aangedaan. Het is trots om de Roep namens God Zelf te willen ontkennen.Alle valse nederigheid leggen we vandaag naast ons neer, zodat we kunnen luisteren naar Gods Stem, die ons onthult wat Hij ons wil laten doen. We twijfelen niet aan onze geschiktheid voor de functie die Hij ons aanbieden zal. We zijn er alleen zeker van dat Hij onze krachten, onze wijsheid en onze heiligheid kent. En als Hij ons waardig acht, dan zijn we dat. Het is slechts arrogantie om er anders over te oordelen.Er is één manier, en slechts één, om te worden bevrijd uit de gevangenschap die jouw plan om te bewijzen dat het onware waar is, jou heeft gebracht. Accepteer in plaats daarvan het plan dat jij niet hebt gemaakt. Oordeel niet over jouw waarde daarvoor. Als Gods Stem jou verzekert dat de verlossing jouw aandeel nodig heeft en dat het grote geheel van jou afhankelijk is, wees er dan zeker van dat dit zo is. De hoogmoedigen moeten zich wel vastklampen aan woorden, bang als ze zijn die te overstijgen en iets te ervaren wat hun standpunt zou kunnen tarten. Maar de nederigen zijn vrij om de Stem te horen die hun zegt wat ze zijn en wat hun te doen staat.Arrogantie maakt een beeld van jezelf dat niet werkelijk is. Het is dit beeld dat huivert en in doodsangst terugdeinst wanneer de Stem namens God jou verzekert dat jij de kracht, de wijsheid en de heiligheid bezit om alle beelden te overstijgen. Jij bent niet zwak, zoals het beeld van jezelf dat is. Jij bent niet onwetend en hulpeloos. Zonde kan de waarheid in jou niet bezoedelen en ellende kan niet dichtbij Gods heilige woning komen.Dit alles verkondigt jou de Stem namens God. En terwijl Hij spreekt, siddert het beeld en probeert het de bedreiging die het niet kent aan te vallen, terwijl het zijn fundament voelt afbrokkelen. Laat het los. De verlossing van de wereld hangt af van jou en niet van dit hoopje stof. Wat kan het de heilige Zoon van God vertellen? Waarom zou hij er zich überhaupt om bekommeren?En zo vinden we onze vrede. We zullen de functie aanvaarden die God ons gegeven heeft, want alle illusies berusten op de eigenaardige overtuiging dat we voor onszelf een andere kunnen maken. Onze eigengemaakte rollen zijn wisselend en lijken te variëren van rouwdrager tot de extatische gelukzaligheid van liefde en liefhebben. We kunnen lachen of huilen, en de dag begroeten met open armen of met tranen. Ons diepste wezen schijnt te veranderen wanneer we duizend stemmingswisselingen ervaren en onze emoties ons hoog verheffen, of ons in wanhoop neersmakken op de grond.Is dit de Zoon van God? Zou Hij zo'n instabiliteit kunnen scheppen en dat Zoon noemen? Hij die onveranderlijk is deelt Zijn eigenschappen met Zijn schepping. Alle beelden die Zijn Zoon lijkt te maken, hebben geen effect op wat hij is. Ze dwarrelen door zijn denkgeest als door de wind opgewaaide bladeren die een ogenblik een patroon vormen, uit elkaar vallen, zich hergroeperen en wegvliegen. Of als luchtspiegelingen die boven een woestijn worden gezien, oprijzend uit het stof.Deze schimmige beelden zullen verdwijnen en je denkgeest onbeneveld en sereen achterlaten, wanneer jij de functie accepteert die jou gegeven is. De beelden die je maakt laten alleen tegenstrijdige doelen ontstaan die vergankelijk en vaag, onzeker en meerduidig zijn. Wie zou standvastig in zijn pogingen kunnen zijn, en zijn energie en geconcentreerde volharding op zulke doelen kunnen richten? De functies die de wereld hoogacht, zijn zo onzeker dat ze op hun zekerst minstens tien keer per uur veranderen. Welke hoop is er dat er bij zulke doelen iets kan worden gewonnen?In liefdevolle tegenstelling daarmee onderscheidt zich, zo zeker als de zon elke morgen terugkeert om de nacht te verjagen, helder en geheel ondubbelzinnig de jou waarlijk gegeven functie. Over de gegrondheid daarvan bestaat geen twijfel. Ze komt van Iemand die geen vergissingen kent, en Zijn Stem is zeker van Haar boodschappen. Die zullen niet veranderen, noch tegenstrijdig zijn. Ze wijzen alle naar één doel, een dat jij kunt bereiken. Jouw plan is misschien onmogelijk, maar dat van God kan nooit mislukken, omdat het in Hem zijn Oorsprong vindt.Doe zoals Gods Stem aangeeft. En als die iets van jou vraagt wat onmogelijk lijkt, denk er dan aan Wie het is die vraagt, en wie het is die weigert. Overweeg dan dit: wie heeft het ‘t meest waarschijnlijk bij het rechte eind? De Stem die namens de Schepper van alle dingen spreekt, die alle dingen precies kent zoals ze zijn, of een vervormd beeld van jezelf, verward, onthutst, onsamenhangend en onzeker van alles? Laat je niet leiden door die stem. Hoor in plaats daarvan een zekere Stem die jou vertelt van een functie die jou gegeven is door jouw Schepper, die Zich jou herinnert en jou aanspoort dat jij je Hem nu herinnert.Zijn zachte Stem roept vanuit het gekende naar de onwetenden. Hij wil jou troosten, ook al kent Hij geen droefheid. Hij wil een teruggave verlenen ook al is Hij compleet: een gave aan jou, ook al weet Hij dat jij alles al hebt. Hij heeft Gedachten die een antwoord zijn op elke behoefte die Zijn Zoon bespeurt, ook al ziet Hij ze niet. Want Liefde moet geven, en wat in Zijn Naam wordt gegeven neemt die vorm aan welke in een wereld van vormen het meest bruikbaar is.Dit zijn de vormen die nooit kunnen misleiden, omdat ze uit Vormloos heid zelf voortkomen. Vergeving is een aardse vorm van liefde die, zoals ze in de Hemel bestaat, geen vorm bezit. Maar wat hier nodig is wordt hier gegeven zoals het nodig is. In deze vorm kun je zelfs hier je functie vervullen, hoewel wat liefde voor je zal betekenen wanneer vormloosheid jou teruggegeven is, nog grootser is. De verlossing van de wereld hangt af van jou die kan vergeven. Dat is jouw functie hier.

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: AI-Assisted Colonoscopy Can Detect Small Colon Polyps As Colorectal Cancer Incidence Increases in Younger Patients, USPSTF Issues New Screening Guidelines. Here's How Nurses Can Encourage Uptake Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Text Messaging Reduces Disparities in Colorectal Cancer Screening USPSTF Recommends Colorectal Cancer Screening Should Begin at 45 Clinical Journal of Oncology Nursing articles: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Colorectal Cancer Screening: A Quality Improvement Initiative Using a Bilingual Patient Navigator, Mobile Technology, and Fecal Immunochemical Testing to Engage Hispanic Adults Oncology Nursing Forum article: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data ONS Course: Prevention, Detection, and the Science of Cancer—Oncology RN ONS Biomarker Database ONS Colorectal Cancer Learning Library American Cancer Society colorectal cancer resources Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42 “[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there's a huge impact on early detection.” TS 4:07 “Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25 “Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29 “Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53 “Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you're like, ‘There's no way they're going to agree to that, so I'm just not going to offer it.' Where we don't offer it, they don't have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18

Op zaterdag 19 november 2005 gaat de telefoon bij de huisarts van wacht: Willy meldt in paniek dat zijn vrouw Gilberte dood in bed ligt in hun woning in Brecht. De arts komt ter plekke en kan inderdaad enkel nog haar overlijden vaststellen. Er zijn geen uiterlijke sporen van geweld te vinden, maar later dat weekend begint de arts toch te twijfelen. Hij neemt het zekere voor het onzekere en stapt maandagochtend naar de politie. Hier is aflevering 162! Zit je met iets? Praat bij Tele-Onthaal over wat jou bezighoudt. Bel anoniem en gratis naar 106 (24u/7d) of chat via tele-onthaal.be Ons pakketje van €68,99, nu voor €44,99 én ook nog eens gratis verzending als je de code VOLKSJURYBE gebruikt. 35% korting dus en zo aan je voordeur bezorgd. Beter wordt het niet :-). Zolang de voorraad strekt, op = op dus haast je! Surf naar wijnbeurs.be/volksjury of wijnbeurs.nl/volksjury voor Nederlandse luisteraars. Bestel nu op emma-matras.be - Tot 60% korting tijdens de ZOMER SOLDEN (01/07 tot 31/07) Ontvang 5% extra korting met de code DEVOLKSJURY5 Voornaamste bronnen: De Morgen - 'Eerst een groot pak frieten, dan een cognac' De Morgen - 'We gingen naar het bos om te vrijen' De Morgen - Betrapt op moord, net voor crematie van slachtoffer De Morgen - Het gevecht van Yolande Magy, de oudste vrouwelijke gedetineerde van het land De Morgen - Magy blijft hardnekkig betrokkenheid moordpogingen ontkennen De Morgen - Na zeven jaar cel veroordeeld tot zeven jaar cel De Morgen - Tot 25 jaar cel gevorderd voor Magy en Van Gorp De Morgen - Veroordeelde Magy: Liever sterven dan naar gevangenis De Morgen - Yolande gaf me vier pillen, daarmee moest ik Gilberte verdoven De Morgen - Yolande Magy schuldig bevonden aan moordpoging met pillen De Morgen - Yolande Magy wint en mag gevangenis verlaten HBvL - Dochter Magy: “Ik heb indertijd verklaringen afgelegd onder druk omwille van mijn kinderen” HBvL - Magy ontkent bedreigingen en stalking van slachtoffer Gilberte Timmermans HBvL - Oudste vrouwelijke gedetineerde van België na 7 jaar vrijgelaten omdat ze geen eerlijk proces kreeg HBvL - Yolande Magy heeft volgens gerechtspsychiater egocentrische kenmerken HBvL - “Yolande Magy vroeg specifiek naar Zolpidem” HBvL - Zaak-Magy: “Wel degelijk aan Marokkaanse kennis dodende materie gevraagd” HLN - Binnenkort zijn uwe man en uw huis van mijSee omnystudio.com/listener for privacy information.

Vandaag het gesprek met Silvia Oostwegel, Impact ondernemer. Silvia zet zich in voor een sociale en duurzame samenleving als directeur en oprichter van Social Handprint by MAEX en als bestuurder van Social Handprint Foundation. Na een studie biologie en diverse banen in het bedrijfsleven, de overheid en als consultant, is zij als ondernemer gestart om profit en non profit organisaties te helpen hun sociale en duurzame prestaties te meten en te versterken. De missie is maatschappelijke waarden leidend te maken. Laten we beginnen… Wat ik zoal leerde van Silvia: 00:00 intro - 03:05 Waarom heeft een bedrijf de social handprint nodig? 04:05 De maatschappelijke waarden veel meer leidend te maken in je handelen. 05:05 Gestart met werken voor sociale burgerinitiatieven, non profit organisaties. 08:10 een impact economie waarbij je naast de financiële balans ook kijkt naar de impact die je hebt in de samenleving. 11:50 De lastige discussie of je Shell als klant wilt of niet. 13:05 De taal van de corporates gebruiken om euros op te halen om daarmee maatschappelijke investeringen te kunnen doen. 14:20 Ons morele kompas. 20:30 Je hebt ander instrumentarium nodig om duidelijkheid te krijgen wat er maatschappelijke gebeurt met de subsidies. 22:05 Hoe besluit ik, bijvoorbeeld als gemeente, waar mijn geld naartoe gaat? 29:15 Het proces om te bepalen welke projecten geld krijgen. 31:20 Drie verschillende producten, een handprint meting, de impuls (geld), en inzichten in een groep. 33:00 Zo zijn de inkomsten verdeeld. 34:40 De rebranding van de Maatschappelijke AEX. 36:15 Wat is het moment dat je besluit voor de rebranding? 37:00 Van een stichting en BV naar een steward owned bedrijf. 40:25 Nog geen winst gemaakt. 43:40 De dynamische balans tussen de korte en lange termijn van de ondernemer. 45:50 De waarde van de social handprint. 47:00 Regelmatig vernieuwen van de terminologie maakt het lastiger, zoals global goals, armoede, circulair, SDGs, brede welvaart. 51:10 Vertel me wat je doet en wij meten wat je doet. 53:55 Wij vragen nooit of je een beleid hebt op diversiteit, we kijken hoe divers is je organisatie. 54:10 Het gaat niet om de modellen, ga wat doen. Meer over Silvia Oostwegel: https://www.linkedin.com/in/silvia-oostwegel-7101687/  https://www.socialhandprint.com Andere bronnen: IDG Achterhoek community hub Chantal Walg Lokalen Lichtenvoorde Tommy Tomato Oscar Circulair Sustainable Development Goals Brede welvaart Kim Putters Kim Putters: ‘Brede welvaart mét de SDG's: de noodzaak van integrale lange termijnvisie' B corp Code voor sociale ondernemingen PSO - Prestatieladder Socialer Ondernemen Theory of Change Video van het gesprek met Silvia Oostwegel https://youtu.be/5vsC4ZP4BlI Kijk hier https://youtu.be/5vsC4ZP4BlI

Confira nesta edição do JR 24 Horas: A polícia do Rio de Janeiro foi às ruas nesta quinta-feira (3) para prender criminosos das duas maiores facções do país. A operação cumpriu mandados de prisão e de busca e apreensão em quatro estados: Rio de Janeiro, São Paulo, Paraná e Mato Grosso do Sul. Os alvos são integrantes do PCC e do Comando Vermelho, que atuavam juntos no tráfico de drogas e armas no Complexo do Alemão, zona norte do Rio. E ainda: ONS determina aumento do uso de usinas térmicas para o fornecimento de energia no país.

Ons praat oor die pad vorentoe vir die families van die Cradock-4. Inflasieverwagtinge daal vir die eerste keer in meer as vier jaar tot laer as 4% - maar wat beteken dit vir die verbruiker? Vandag is Wêreld Plastieksakvrye-dag.

NESTA EDIÇÃO. Preço do barril de petróleo em trajetória de queda com menor prêmio de risco para o conflito entre Israel e Irã. ONS ajusta limites de escoamento de energia do Nordeste ao Sudeste para tentar reduzir os cortes de geração. Setor de biocombustíveis é um dos grandes potenciais consumidores de hidrogênio de baixo carbono, aponta EPE. Financiamento para a transição energética foi um dos pontos de destaque da Conferência de Bonn, que ajudou a preparar a pauta da COP30.

 Critical Thinking  Combatting Domestic Abuse (Part 2) Black Spy Podcast 199, Season 20, Episode 0010 Below is a concise yet data-rich overview of the current domestic violence situation in the UK, as discussed in Part One of the Black Spy Podcast, featuring host Carlton King (“The Black Spy”), neuroscientist Dr Rachel Taylor, and journalist Firgas Esack. Host Carlton King (“The Black Spy”) sits down with Dr Rachel Taylor, a leading neuroscientist, and journalist Firgas Esack, to dive deep into these figures. This episode explores not only the statistics but the human, systemic, and gendered dimensions of domestic violence—shining light on under‑reported experiences, prevention strategies, and why these numbers matter. This is Part Two of an extremely informative series on Combatting Domestic Violence—essential listening for anyone looking to understand and address this crisis in modern Britain.

Zondag 29 juni: Waterschaarste is een begrip geworden dat niet enkel in Zuiderse landen is ingeburgerd. Ons land staat er zelfs zo slecht voor dat het enkel Griekenland en Cyprus moet laten voorgaan van Europese landen met de grootste waterstress. Wat zijn de oorzaken? En welke aanpassingen zijn noodzakelijk om onze watervoorziening te blijven garanderen? Collega Francesca Vanthielen vraagt het aan Hans Goossens, directeur-generaal van De Watergroep, het grootste drinkwaterbedrijf in Vlaanderen. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie. De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst. Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen. Onafhankelijk, relevant, telkens constructief en toekomstgericht.

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

Podlitiek spring weg met 'n splinternuwe onderhoudreeks! Louis en Arno gesels met Prof Fransjohan Pretorius oor die waarde daarvan om jou geskiedenis te ken. Hy deel ook 'n interessante staaltjie of twee uit die Afrikaner se geskiedenis. Verskoon die swak klankgehalte. (Ons maak maar asof ons doelbewus van ou tegnologie gebruik gemaak het vir die geskiedenis-episode.)Podlitiek word aangebied deur:Louis BoshoffArno RoodtErnst van Zyl

“That's what metastatic breast cancer looks like now—patients can live an extended period of time. And sometimes I think we forget to cheer for stable disease. I tell patients they can live with weeds in their garden; they just can't let the weeds take over their garden. And today we don't have a cure. We live in a rapidly changing time in oncology, and so there's just so much hope right now that we can offer patients,” ONS member Kristi Orbaugh, RN, MSN, RNP, AOCN®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about patient communication in the metastatic breast cancer setting. This podcast episode was developed by ONS through a sponsorship from Lilly. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options What Is HER2-Low Breast Cancer? ONS books: Guide to Breast Care for Oncology Nurses ONS course: Breast Cancer Bundle Oncology Nursing Forum article: Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS Biomarker Database American Cancer Society breast cancer resources METAvivor National Cancer Institute resources: Breast cancer—Patient version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I think the most important and vital piece of having those conversations is making sure that we know—really know—that patient, because if we know them, that helps guide what they're needing right then, helps guide our verbiage, helps guide disciplines that we bring in.” TS 2:04 “What do they want to hear? I've been in practice a really, really long time, and I've had the entire spectrum. I've had patients say, ‘Tell me every single detail.' I mean, they want pictures. They want graphs. They want me to draw things. I've even had patients that want me to take markers and mark their body parts. … And then I've had patients that say, ‘I don't want to know anything. I trust my healthcare team. I'm going to proceed with treatment, but I really don't want to know anything.'” TS 3:40 “Remember to make things as simple as possible until we really know what the patient knows. We don't send our children to school and start them out in eighth grade; we send them to kindergarten for a reason. So we get basic information, and then we build on that. And I think we need to remember that when we're doing our patient education, whether it's regarding new chemotherapy or treatment plans or palliative care, we've got to remember to start simple. And maybe we build on that very quickly, or maybe it takes a bit more time. Number one—I actually think it helps with adherence because patients understand what we're asking of them and why we're asking that of them.” TS 12:00 “I think what's really kind of key to keep in mind is that patients are going to seek information. And so, we need to make sure that we're giving them really good, reliable, durable information because if we are not giving them good websites, if we're not giving them good written material, if we're not giving them good verbal information and education, they're going to contact ‘Dr. Google.' Dr. Google is good for a lot of things, but sometimes patients can go down a rabbit hole that's not appropriate or not accurate. That's not a good place for them to be.” TS 14:35 “If we find biomarkers that we call actionable, meaning that we find this mutation and we have a drug that blocks that mutation, that is what is going to guide and drive our treatment. Sometimes that can take a bit of time, right? And if we have a patient and they just find out they have metastatic disease, will they want treatment yesterday. And I understand that. … But frequently there is a very important period of waiting and allowing us to learn that enemy better by reviewing genomic testing, looking at that next-generation sequencing, looking at any positive biomarkers in breast cancer. They may have started out ER/PR positive. Are they still ER/PR positive?” TS 23:46 “I think when we're talking about goals of care, first of all, we need to make sure that the patient understands, when we're talking about metastatic disease today…, this is not a disease that we can cure, but hopefully it's a disease that we can manage for years to come. With that in mind, what's important to that patient? What is important to that patient in terms of life goals? What's important to that patient in terms of toxicities that they will allow and toxicities that they won't allow? TS 29:22 “If don't have a lot of medical knowledge, taking a pill seems less important than getting an IV. It seems like a bigger deal if I would miss getting my IV therapy. ‘Oh, whoops, I forgot to take a pill. Maybe it's not such a big, important piece of my treatment.' So education—when we set that patient down, helping them understand how this drug works, mechanism of action in a simple term, why it's important to take it as scheduled, why it's important to take it with food or without food, why it's important to take it consistently.” TS 34:41

A parade of pauses WAR! Middle East at it again Oracle earnings - wow! Tesla robotaxi spotted PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter ** Look At Album Art ** - So bad  Warm-Up - More pausing floated - We have a CHYNA deal -  kind of - Saying goodbye to Brian Wilson - Tesla - back in buy mode Markets - War! Middle East again (US seems to be helping ?) - Within 2% if ATH and then... - Oracle blows the roof off - UK economy shrinks - bigly ***A NEW Closest to the Pin! Middle East Again - Israel launched a series of airstrikes against Iran early Friday morning local time, targeting locations it said were related to Iran's nuclear program, sparking market fears of a wider conflict. - Mohammad Hossein Bagheri, chief of the Iranian Armed Forces and the country's most senior military official, was killed during the strikes, alongside the commander-in-chief of Iran's Islamic Revolutionary Guard Corps, Hossein Salami, Iranian state media reported. - The Israeli airstrikes also targeted and killed two of Iran's leading nuclear scientists, Fereydoun Abbasi-Davani and Mohammad Mehdi Tehranchi, according to Iranian news outlets. - Odd timing? - Markets initially took it better than expected - until Iran stuck back Valuations - As of the most recent update on June 5, 2025, the forward P/E ratio of the S&P 500 is 21.70. This reflects a decline from 22.44 in the previous quarter and 25.20 one year ago, 10 -year average is about 19 PE Forward Chart Something we discussed on TDI  - Presidential Cycles - The U.S. stock market tends to follow a four-year cycle aligned with presidential terms. Historically, the first year of a president's second term (4 years apart in this case) often mirrors the first year of a new presidency in terms of market behavior—marked by uncertainty, policy re-calibration, and sometimes muted performance - While the first half of the first year can be choppy due to post-election adjustments and early policy moves, the second half—especially Q4—has historically shown stronger performance. This is often attributed to: Stabilizing policy direction after early-year volatility Investor optimism around fiscal planning and budget cycles Seasonal tailwinds like the holiday rally and year-end portfolio rebalancing Presidential Cycle UK Economy- This is why we need to dig further than the headline (more beneath the surface) - The U.K. economy shrank sharply in April as global trade tariffs and domestic tax rises kicked in, data showed Thursday. - The latest monthly growth figures from the Office for National Statistics showed the U.K. economy contracted 0.3% month on month in April, following growth of 0.2% in March. - It was also more than the 0.1% fall economists were expecting. - “After increasing for each of the four preceding months, April saw the largest monthly fall on record in goods exports to the United States with decreases seen across most types of goods, following the recent introduction of tariffs,” --- The real culprit: ----- Domestic tax rises have also been blamed for the steep decline in economic activity. British businesses have been confronted with an increase in national insurance contributions and rise in the minimum age from the start of April, while a temporary tax break on property purchases also came to an end in March. - ----The change in the Stamp Duty Land Tax (paid when buying property or land) in April meant there was a decrease of 63.5% in U.K. residential property transactions from the previous month, the ONS noted, with buyers rushing to complete purchases before the tax break ended. US Economy - U.S. consumer prices increased less than expected in...

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

“[My mom] would always be very inspirational whenever I would see her studying so long. And when she finally got to be a nurse, I always admired her vocation and compassion with her patients. She would always go above and beyond for all of her patients. I also got inspired a lot by my brother, as well, just seeing how passionate he was for caring for his patients for the families as well, and helping them deal with the any grief or loss that they were experiencing, Carolina Rios, MSN, RN, CPhT, told Valerie Burger, RN, MA, MS, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about families in nursing. Burger spoke with Carolina, her mother Lissette Gomez-Rios, MSN, APRN, AGACNP-BC, FNP-BC, OCN®, BMTCN®, and her brother Carlos Rios, BSN, RN, BMTCN®, about how having multiple nurses in their family has affected them personally and professionally. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 327: Journey of a Student Nurse: Choosing Oncology Nursing and the Value of a Professional Home ONS Voice articles: Innovation Inspires Hope: A Nurse's Journey of Passion and Purpose When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places Is Work–Life Balance Possible? The Evidence Says It Isn't—Rather, It's About Reframing Our Thinking ONS Nurse Well-Being Learning Library Oncology Nursing Foundation Resiliency Resources Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Lissette: “Being in the oncology nursing as a family, when I feel the necessity to talk to them, they listen to me. They pay attention, and we help each other to cope, especially when there is a loss of our patients, so we help each other. We are understanding. We give them compassion and the advice that we need.” TS 6:51 Carlos: I remember growing up—and [my mom] would always be in school and in the healthcare field, so I knew growing up I wanted to be in the healthcare field. She was the one that guided me into going to nursing because at a certain point, I wasn't sure what I was going to be doing. She guided me, and once I started doing nursing, this has been the career I want to do, I want to continue doing. I'm very grateful for her guiding me into nursing.” TS 9:48 Carolina: “Anytime I had a question I would ask them. They would always help me out, make sure I really understood. It would actually be a little funny because sometimes they would overexplain, and I was a little overwhelmed, and I would have to be like, ‘OK, let's dial it back. Let's get back to the basics.'” TS 14:22